Reuters logo
BRIEF-Argenx publishes seminal data supporting therapeutic potential of ARGX-110
December 29, 2016 / 6:22 AM / a year ago

BRIEF-Argenx publishes seminal data supporting therapeutic potential of ARGX-110

Dec 29 (Reuters) - Argen X BV :

* Argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine

* Publication of new preclinical data on CD70/CD27 pathway that provide further rationale for ARGX-110 therapy for treatment of acute myeloid leukemia (AML)

* ARGX-110, a simple antibody targeting CD70, is currently being evaluated in a phase I/II study in combination with azacitidine in newly diagnosed AML patients

* Data demonstrate that CD70/CD27 is highly expressed on AML blasts and leukemic stem cells in newly diagnosed AML patients regardless of cytogenetic factors or patient’s risk class

* Data show CD70/CD27 pathway to be critical in biology of leukemic stem cells, and critical therapeutic intervention using a CD70-targeted antibody to enable selective targeting of leukemic stem cells without impacting hematopoietic stem cells, resulting in a survival benefit in preclinical AML models Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below